Studies Investigating Predictive Ability of Interim PET Imaging in NHL
| Results | ||||
| Study | Patient population | Cycles completed before imaging | PET+ | PET− |
| Lin, 2007 (54) | 92 DLBCL patients (11 limited, 81 advanced) | 2 (CHOP, R-CHOP, ACVBP, R-ACVBP) | 2-y EFS: 51% | 2-y EFS: 79% |
| Casasnovas, 2011 (55) | 102 NHL patients | 2–4 (R-ACVBP, R-CHOP) | 2-y PFS: 73% (IHP), 79% (D5PS) | 2-y PFS: 77% (IHP), 88% (D5PS) |
| Cashen, 2011 (56) | 50 advanced-DLBCL patients | 2 (R-CHOP) | 2-y EFS: 63% | 2-y EFS: 85% |
| Yang, 2011 (57) | 161 DLBCL patients (94 limited, 67 advanced) | 3–4 (R-CHOP) | 3-y PFS: 52.5% | 3-y PFS: 88.3% |
| Yoo, 2011 (28) | 155 DLBCL patients (68 limited, 87 advanced) | 2–4 (R-CHOP) | 3-y PFS: 66%* | 3-y PFS: 84%* |
| Dupuis, 2012 (33) | 121 follicular lymphoma patients | 4 (R-CHOP) | 2-y PFS: 61% | 2-y PFS: 86% |
| Pregno, 2012 (29) | 88 DLBCL patients (29 limited, 59 advanced) | 2–4 (R-CHOP) | 2-y PFS: 72%* | 2-y PFS: 85%* |
| Safar, 2012 (58) | 112 DLBCL patients (21 limited, 91 advanced) | 2 (R-CHOP, R-ACVBP) | 3-y PFS: 47% | 3-y PFS: 84% |
| Itti, 2013 (59) | 114 DLBCL patients | 2 (rituximab) | 3-y PFS: 59% | 3-y PFS: 81% |
| Carr, 2014 (60) | 61 DLBCL patients (24 limited, 37 advanced) | 2–3 (R-CHOP) | 2-y EFS: 58%; 2-y OS: 72% | 2-y EFS: 90%; 2-y OS: 93% |
| Khong, 2014 (31) | 24 natural killer/T-cell lymphoma patients | 2 −3 (SMILE) | 2-y PFS: 17%; 2-y OS: 17% | 2-y PFS: 62%; 2-y OS: 81% |
| Nols, 2014 (61) | 73 DLBCL patients (23 limited, 50 advanced) | 3–4 (R-CHOP, ACVBP) | PFS: 47% (D5PS) | PFS: 84% (D5PS) |
| Huang, 2015 (30) | 32 DLBCL patients (9 limited, 23 advanced) | 2 (R-CHOP) | 2-y PFS: 82%* | 2-y PFS: 88%* |
| Fukumoto, 2015 (32) | 79 natural killer/T-cell lymphoma patients | 2–4 | 5-y PFS: 9.2% | 5-y PFS: 66% |
| Mamot, 2015 (8) | 138 DLBCL patients (64 limited, 74 advanced) | 2 (R-CHOP) | 2-y EFS: 48%; 2-y OS: 88%* | 2-y EFS: 74%; 2-y OS: 91%* |
↵* Nonsignificant.
ACVBP = adriamycin, cyclophosphamide, vindesine, bleomycin, and prednisone; R-ACVBP = rituximab, adriamycin, cyclophosphamide, vindesine, bleomycin, and prednisone; EFS = event-free survival; IHP = International Harmonization Project criteria; SMILE = dexamethasone, methotrexate, ifosfamide, l-asparaginase, and etoposide; OS = overall survival.